By analyzing existing basic indicators between Immunoprecise Antibodies and Mustang, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Mustang with a short position in Immunoprecise Antibodies. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Immunoprecise is to check how much profit was generated for every dollar of assets it reports. Immunoprecise Antibodies retains a negative application of resources of -9.67 (percent), losing $0.0967 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Immunoprecise Antibodies shows how discouraging it operates for each dollar spent on its resources.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in Immunoprecise Antibodies. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its
performance over time. Several factors influence the investment perspective on Immunoprecise Antibodies, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
Watch out for price decline
Please consider monitoring Immunoprecise Antibodies on a daily basis if you are holding a position in it. Immunoprecise Antibodies is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Immunoprecise Antibodies stock to be traded above the $1 level to remain listed. If Immunoprecise Antibodies stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Immunoprecise Antibodies's Liquidity
Immunoprecise Antibodies
financial leverage refers to using borrowed capital as a funding source to finance Immunoprecise Antibodies ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Immunoprecise Antibodies financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Immunoprecise Antibodies' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Immunoprecise Antibodies' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Immunoprecise Antibodies's total debt and its cash.
Going after Immunoprecise Financials
Cash and Equivalents Breakdown
Now, let's check Immunoprecise Antibodies cash and equivalents. In accordance with the recently published financial statements, Immunoprecise Antibodies has 15.72
M in Cash and Equivalents. This is 98.08% lower than that of the Healthcare sector and 96.48% lower than that of the
Biotechnology industry. The cash and equivalents for all United States stocks is 99.42% higher than that of the company. As for Mustang Bio we see cash and equivalents of 129.92
M, which is 70.94% lower than that of the Biotechnology
| IPA | 15.72 Million | 2.65 |
| Sector | 447.12 Million | 75.43 |
| MBIO | 129.92 Million | 21.92 |
Our perspective of the current Immunoprecise Antibodies rise
Current Information Ratio is up to -0.09. Price may slip again. Immunoprecise Antibodies exhibits very low volatility with skewness of 0.45 and kurtosis of 0.3. However, we advise investors to further study Immunoprecise Antibodies technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunoprecise Antibodies' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunoprecise Antibodies' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Immunoprecise Antibodies Implied Volatility
Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.
The Current Takeaway on Immunoprecise Antibodies Investment
Whereas many of the other players under the biotechnology industry are still a bit expensive, Immunoprecise Antibodies may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Immunoprecise Antibodies.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Immunoprecise Antibodies. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
